RVMD
The table below shows Revolution Medicines, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$354.17M | -$194.44M | -$160.56M | -$62.39M | -$55.16M | -$37.25M |
| Capital expenditure | $1.54M | $3.27M | $3.17M | $1.76M | $1.89M | $3.58M |
| Investing cash flow | $172.62M | -$15.95M | -$247.97M | $4.00M | $44.02M | $2.31M |
| Dividends paid | - | - | - | - |
Revolution Medicines, Inc. reported operating cash flow of -$897.74M for fiscal year 2025. That is down 61.0% from -$557.44M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from $1.21M (FY 2018) to -$897.74M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $238.74M | $874.00K | $810.00K | $324.20M | $305.00K | $282.26M |